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Childhood-onset systemic lupus erythematosus (cSLE)
represents 15-20% of all SLE cases and is in general
associated with a more aggressive disease course and
more rapid damage accrual than adult-onset SLE. Disease
expression varies according to ethnicity, with more severe
disease course in non-Caucasian ethnic groups. The
majority of patients with cSLE develop damage within
5-10 years of disease onset, most frequently involving the
musculoskeletal, ocular, renal and central nervous sys-
tems. Premature atherosclerosis and osteoporosis have
become increasingly prevalent comorbidities in cSLE
patients.
Treatment of cSLE is challenging and is further com-
plicated by an unpredictable disease course, adolescent
noncompliance and long requirement for therapy. New
therapeutic regimens combining immunosuppressive
agents and targeted B-cell depletion often provide
improved disease control and follow the oncologic
model of remission induction and maintenance therapy.
Management of children with SLE must include also
prevention of medication side effects on growth, delayed
puberty, development and fertility. Optimal management
of an adolescent with SLE should take into account also
patient’s quality of life, psychosocial development and
organization of successful transition from pediatric to
adult care.
The antiphospholipid antibody syndrome (APS) is a
multisystemic autoimmune disease characterized by
thromboembolic events, pregnancy morbidity, hematolo-
gic, dermatologic, neurologic and other manifestations
in the presence of elevated titers of antiphospholipid
antibodies (aPL). APS may occur as an isolated clinical
entity (primary APS) or in association with autoimmune
diseases, infections and malignancies. Multiple patho-
genic mechanisms have been proposed by which aPL
may predispose to thrombosis including interaction
between aPL and endothelial cells, platelets, monocytes,
activation of the complement system, and interaction
with the proteins involved in the regulation of the coa-
gulation cascade.
Management in all patients with APS include avoidance
of additional risk factors for thrombosis. Patients with
persistently positive aPL, in particular those with lupus
anticoagulants (LA), have a high risk for recurrent throm-
bosis and should receive long-term anticoagulation with
warfarin. The standard treatment in APS patients with
venous or non-cerebral arterial thromboembolism consist
of oral anticoagulation at a target INR of 2.0-3.0. However,
it is essential to individualize treatment according to the
presence of additional thrombophilic risk factors and the
aPL profile (multiple aPL antibodies, high titers of aCL
and/or anti-b2GPI, presence of LA). An improved under-
standing of the pathogenic mechanisms by which aPL
induce thrombosis has suggested some innovative treat-
ments such as new anticoagulant and antiplatelet drugs,
hydroxychloroquine, statins, complement inhibitors, ritux-
imab and other targeted therapies.
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